Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy

This trial studies the mechanisms of metabolic and hormone action on plaque formation in brain and carotid vessels in patients with prostate adenocarcinoma. Studying the biomarkers in the laboratory may help doctors know the impact of androgen deprivation on metabolic, brain and cardiovascular endpoints.

Study Overview

• Status: Terminated
• Conditions: Prostate Adenocarcinoma
• Intervention / Treatment: Other: Quality-of-Life Assessment; Procedure: Evaluation

Detailed Description

OUTLINE:

Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.

• Study Type: Observational
• Enrollment (Actual): 2

Contacts and Locations

Study Locations

• United States
  • Washington
    • Seattle, Washington, United States, 98109
      • Fred Hutch/University of Washington

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

• Sampling Method: Non-Probability Sample

Study Population

Participants with prostate adenocarcinoma

Description

Inclusion Criteria:

• Signed informed consent
• Histologically confirmed adenocarcinoma of the prostate
• Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
• No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans

• Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:

  • Prior myocardial infarction >= 30 days before enrollment

  • Prior revascularization procedure >= 30 days before consent, including:

    • Coronary artery stent placement or balloon angioplasty
    • Coronary artery bypass graft surgery
    • Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
    • Carotid endarterectomy surgery
    • Vascular bypass surgery of the iliac, femoral, or popliteal artery
  • Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
  • Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
  • Ankle-brachial pressure index < 0.9 at any time point before enrollment
• Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months

Exclusion Criteria:

• No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
• Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
• Plans to start or continue treatment with an investigational product after enrollment
• Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
• Prior or planned surgical castration
• Poorly controlled hypertension at time of study entry, as judged by the investigator
• Myocardial infarction or stroke < 30 days prior to enrollment
• Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
• Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
• Mental incapacity or language barrier precluding adequate understanding or cooperation
• Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
• Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
• Estimated glomerular filtration rate (eGFR) < 45
• History of allergy to gadolinium contrast agent

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Clinical Evaluations; Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.	Other: Quality-of-Life Assessment; Ancillary studies; Procedure: Evaluation; Undergo clinical evaluations

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy	Change From Baseline visual characterization scan results at 12 months	12 Months
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results	Change from baseline standardized uptake values in select regions of interest at 12 months	12 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cognitive test results: Story recall	Change in baseline Story Recall results at 12 months	12 months
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)	Change in baseline MOCA score results at 12 months	12 Months
Cognitive Test Results: Change in Clinical Dementia Rating Scale	Change in baseline Clinical Dementia Rating Scale score at 12 months	12 Months
Cognitive Test Results: Digit span	Change in baseline Digit span results at 12 months	12 Months
Cognitive Test Results: Letter number sequencing	Change in baseline Letter number sequencing results at 12 months	12 Months
Cognitive Test Results: Stroop Test Results	Change in baseline Stroop Test Results at 12 months	12 Months
Cognitive Test Results: Symbol Digit Modalities Test	Change in baseline Symbol Digit Modalities Test score at 12 months	12 Months
Cognitive Test Results: Visuo-Spatial Learning Test	Change in baseline Visuo-Spatial Learning Test results at 12 months	12 Months
Cognitive Test Results: Rey auditory verbal learning test (RVLT)	Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months	12 Months
Inflammatory and immune markers: Change in CRP	Change in baseline CRP values at 12 months	12 Months
Inflammatory and immune markers: Change in IGFBP3	Change in baseline IGFBP3 at 12 months	12 Months
Inflammatory and immune markers: Change in IGFBP1	Change in baseline IGFBP1 at 12 months	12 Months
Inflammatory and immune markers: Change in IGF-1	Change in baseline IGF-1 at 12 months	12 Months
Inflammatory and immune markers: Change in IL-6	Change in baseline IL-6 at 12 months	12 Months
Metabolic Markers: Change in HgbA1C	Change in baseline HgbA1C at 12 months	12 Months
Metabolic Markers: Change in Estradiol	Change in baseline Estradiol at 12 months	12 Months
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)	Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months	12 Months
Metabolic Markers: Change in Leptin	Change in baseline Leptin at 12 months	12 Months
Metabolic Markers: Change in Adiponectin	Change in baseline Adiponectin at 12 months	12 Months
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)	Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.	12 Months

Collaborators and Investigators

• Sponsor: University of Washington
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Evan Yu, Fred Hutch/University of Washington Cancer Consortium

Study record dates

Study Major Dates

• Study Start (Actual): October 8, 2019
• Primary Completion (Actual): March 12, 2020
• Study Completion (Actual): March 12, 2020

Study Registration Dates

• First Submitted: September 12, 2018
• First Submitted That Met QC Criteria: October 22, 2018
• First Posted (Actual): October 24, 2018

Study Record Updates

• Last Update Posted (Actual): December 10, 2020
• Last Update Submitted That Met QC Criteria: December 8, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Adenocarcinoma
• Other Study ID Numbers: RG1001903; 9939 (Other Identifier: FHCRC); NCI-2018-01618 (Registry Identifier: CTRP); 5P30CA015704 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No